2-Feb-2026
No headlines found.
ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 31-Dec 8:30 AM ET)
ICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Thu, 20-Nov 8:30 AM ET)
ICU Medical Announces Third Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Icu Medical trades on the NASDAQ stock market under the symbol ICUI.
As of February 2, 2026, ICUI stock price climbed to $151.45 with 217,688 million shares trading.
ICUI has a beta of 0.50, meaning it tends to be less sensitive to market movements. ICUI has a correlation of 0.05 to the broad based SPY ETF.
ICUI has a market cap of $3.74 billion. This is considered a Mid Cap stock.
Last quarter Icu Medical reported $537 million in Revenue and $2.03 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.72.
In the last 3 years, ICUI traded as high as $212.43 and as low as $78.28.
The top ETF exchange traded funds that ICUI belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
ICUI has underperformed the market in the last year with a price return of -7.9% while the SPY ETF gained +16.8%. However, in the short term, ICUI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.1% vs +2.2% return in SPY. But in the last 2 weeks, ICUI shares have been beat by the market, returning -3.0% compared to an SPY return of +0.5%.
ICUI support price is $145.35 and resistance is $154.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICUI shares will trade within this expected range on the day.
